Oxeglitazar (also known as EMD 336340 or LM 4156), an orally administered poorly water-soluble dual peroxisome proliferator-activated receptor α/γ agonist. This drug was used in the treatment of type II diabetes mellitus and metabolic syndrome. In addition, oxeglitazar participated in phase I trials for the gout treatment; however, this study was halted. Information about the further development of this drug is not available.

Sodium nivimedone (BRL10833) is an orally administered anti-allergic agent with similar properties to DSCG. Nivimedone inhibited IgE-mediated passive cutaneous anaphylactic (PCA) reactions in the rat and the antigen-induced release of histamine from human lung passively sensitized with atopic serum. The pharmacological potency of sodium nivimedone when compared to DSCG was 42 times greater in the human lung system and approximately ten times greater in rat PCA. In addition, single doses of sodium nivimedone given by mouth inhibited antigen-induced bronchoconstriction in man.